ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0763

What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset

Francesca Ridella1, Roberta Naddei2, Maddalena Spelta2, Cristina N. Herrera3, Clara Malagon4, Olga Arguedas5, Amparo Ibanez Estrella6, Nicola Ruperto7, Angelo Ravelli8 and Alessandro Consolaro9, 1Università degli Studi di Genova Genoa, Italy, Genova, Italy, 2Istituto Giannina Gaslini, Genova, Italy, 3Hospital de Ninos Roberto Gilbert Elizalde, Rheumatology, Guayaquil, Ecuador, Paediatric Rheumatology International Trials Organisation (PRINTO), Guayaquil, Ecuador, 4Hospital Universitario Simon Bolivar, Clinica infantil Colsubsidio, Facultad de Medicina, Post Grado Reumatologia Pediatrica, Universidad El Bosque, Bogota, Colombia, Paediatric Rheumatology International Trials Organisation (PRINTO), Bogotà, Colombia, 5Hospital Nacional de Ninos Dr Carlos Saenz Herrera, Servicio de Immunologia y Reumatologia pediatrica, San Josè, Costa Rica, Paediatric Rheumatology International Trials Organisation (PRINTO), San Josè, Costa Rica, 6National Institute Salud del Nino, Rheumatology Service, Brena, Lima, Peru, Paediatric Rheumatology International Trials Organisation (PRINTO), Lima, Peru, 7Istituto Giannina Gaslini, Paediatric Rheumatology International Trials Organisation (PRINTO), Genova, Italy, 8Istituto Giannina Gaslini, Genoa, Italy, 9Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy

Meeting: ACR Convergence 2021

Keywords: JIA, Outcome measures, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Parent- and child-reported outcomes (PCROs) reflect the parent and child perception of rheumatic disease course and effectiveness of therapeutic interventions. Among PCROs for the assessment of patients with juvenile idiopathic arthritis (JIA), the most widely adopted is the parent/patient global evaluation or well-being visual analogue scale (WB-VAS). Several studies in JIA have highlighted the discrepancies in the assessment of the disease status between the physician and the parent/patient. This difference might be due to the WB-VAS measuring a broader construct than the physician global assessment (PGA). Aim of this study is to evaluate in a large multinational sample of JIA patients the disease characteristics of subjects with a PGA score of 0 and with an increased WB-VAS score.

Methods: Data from the multinational dataset of patients in the Epidemiology Treatment and Outcome of Childhood Arthritis study were analyzed. We have included only subjects with a PGA score of 0. PCROs were collected through the juvenile arthritis multidimensional assessment report. We compared demographic features, socio-economic status, level of education, subtype of JIA diagnosis and the main PCROs (pain level, presence of morning stiffness, count of joints with swelling or pain, functional ability, disease activity level, ongoing therapy, presence of medications side effects and health related quality of life between subjects with WB-VAS ≤ 1 and > 1.

Results: a total of 3537 patients were sorted into two groups according to the WB_VAS score: 2862 subjects were included in a first group (WB_VAS ≤1); 675 in a second one (WB-VAS >1). Respectively, 17,6% vs 18,1% of families belonged to the lower socio-economic status, 70,5% vs 71% to the intermediate, 11,9% vs 10,8% to the higher. The percentages of patients in the three levels of education was not different in the two groups:20,2% and 22% in the lower, 48,9% and 50,1% in the intermediate, 30,8% and 27,9% in the higher level of education. No significant difference was observed in the distribution of JIA categories in the two groups. Subjects in first group were younger at disease onset (5.6 vs 6.4 years). Comparison of main PCROs results is presented in the table.

PCROs

WB_VAS ≤1 WB_VAS >1 p
VAS_Pain (average)

0.3 (0.9) 2.4 (2.4) < 0.001
Presence of morning stiffness (%) 227 (8.0)

285 (42.4)

< 0.001
Patients under treatment (%) 1919 (67.2)

540 (80.2)

< 0.001
Reporting side effects (%) 421 (22.1)

236 (43.9)

< 0.001
Juvenile Arthritis Functionality Scale (JAFS)Total Score (average) 0.5 (1.6)

3.0 (4.4)

< 0.001
JIA Quality of Life (JQL) Total Score (mean)

1.6 (2.3)

6.4 (4.4)

< 0.001
VAS-Disease Activity (average) 0.4 (1.3)

2.3 (2.4)

< 0.001
Count of active joints (average) 0.2 (0.7)

1.4 (2.2)

< 0.001

Conclusion: we have analyzed the variables that might determine a difference between the physician’s assessment of inactive disease and the parent’s/patient’s perception of well-being. In particular, socio-economic status, level of education, and gender representation seem not to impact on the general perception of well-being, while pain seems to have the greatest influence on the parent/patient quality of life assessment. Finally, children with lower WB-VAS score had a younger disease onset.


Disclosures: F. Ridella, None; R. Naddei, None; M. Spelta, None; C. N. Herrera, None; C. Malagon, None; O. Arguedas, None; A. Ibanez Estrella, None; N. Ruperto, Albynx, 6, AstraZeneca, 6, Biogen, 6, Boehringer, 6, Hoffman-La Roche, 1, 5, Pfizer, 1, 5, Novartis, 1, 5, Takeda, 6, Eli Lilly, 1, 5, Bristol Myers and Squibb, 1, 5, GSK, 1, 5, Janssen, 1, 5, EMD Serono, 6, Merck, 6, R-Pharma, 6, R-Pharma, 6, Sanofi, 6, Servier, 6, Sinergie, 6, Sobi, 1, 5, Aurinia, 6, Centrical Global, 6, Domain Terapeutics, 6, Idorsia, 6; A. Ravelli, Abbvie, 2, 6, BMS, 2, 6, Pfizer, 2, 6, Hoffmann-La Roche, 2, 6, Novartis, 2, 6, Centocor, 2, 6, Anjelini Holding, 2, 6, Reckitt Benckiser, 2, 6; A. Consolaro, Pfizer, 5, 6, AbbVie, 6, AlfaSigma, 5.

To cite this abstract in AMA style:

Ridella F, Naddei R, Spelta M, N. Herrera C, Malagon C, Arguedas O, Ibanez Estrella A, Ruperto N, Ravelli A, Consolaro A. What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/what-does-the-patient-well-being-vas-tell-us-when-the-physician-global-assessmentscore-is-zero-analysis-of-a-large-multinational-dataset/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-does-the-patient-well-being-vas-tell-us-when-the-physician-global-assessmentscore-is-zero-analysis-of-a-large-multinational-dataset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology